Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axicabtagene ciloleucel as First-Line Therapy in High-Risk Large B-Cell Lymphoma
NCT03761056Phase 2Completed
- Sponsor
- Kite Pharma
- Start
- Jan 2019
- Primary completion
- Oct 2023
- Modality
- CAR-T Cells
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Kite Pharma. Primary endpoint: Complete Response Rate up to 4 years. Started Jan 2019; status: completed.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03761056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03761056.